Nov 17, 2020 / 07:20PM GMT
Biren N. Amin - Jefferies LLC, Research Division - MD and Senior Equity Research Analyst
Welcome, everyone, to the Jefferies London Virtual Health Care Conference. My name is Biren Amin. I'm one of the biotech analysts here at Jefferies. And I'd like to welcome our next company, IGM Biosciences and their CEO, Fred Schwartzer. So welcome, Fred, for participating in this fireside.
Fred M. Schwarzer - IGM Biosciences, Inc. - CEO, President & Director
Thanks very much. Really appreciate the opportunity.
Questions and Answers:
Biren N. Amin - Jefferies LLC, Research Division - MD and Senior Equity Research AnalystSo maybe to start off for those that aren't not familiar with IGM. You have a unique monoclonal antibody platform in researching and developing IGM, format monoclonal antibodies. Maybe just talk about this platform relative to the IgG peers.
Fred M. Schwarzer - IGM Biosciences, Inc. - CEO, President & Director
Sure. That's my pleasure. Well, let me step